Clinical Trial

Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 23, 2024 (before its estimated January 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to establish a personalized model of prognosis stratification for patients with advanced-stage hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular target therapies.
Trial Details
NCT Number NCT06607120
Lead Sponsor Zhongda Hospital
Conditions Hepatocellular Carcinoma
Enrollment 950 participants
Start Date 2024-06-01
Primary Completion 2025-01-31 (estimated)
Study Completion 2025-03-01 (estimated)
Updated on ClinicalTrials.gov 2024-09-23